MNX1 was highly expressed in the pCR group in both the public database and data obtained from our center, suggesting that MNX1 may be used to predict the sensitivity of neoadjuvant chemotherapy in patients with HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.